Rigel Pharmaceuticals Inc. (RIGL)
$45.99
$-0.49
(-1.05%)
As on 31-Aug-2026 14:34EDT
Market cap
$868 Mln
Revenue (TTM)
$277 Mln
P/E Ratio
2.8
P/B Ratio
2.1
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
1.3 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
8.7
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$17
-
Face value
--
-
Shares outstanding
18,679,864
10 Years Aggregate
CFO
$-472.76 Mln
EBITDA
$-528.28 Mln
Net Profit
$-561.60 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Rigel Pharmaceuticals (RIGL)
| 7.4 | 20.8 | 50.8 | 18.4 | 55.6 | 3.9 | 1.6 |
|
BSE Sensex
| -9.1 | -1.2 | 2.9 | -3.6 | 5.7 | 6.2 | 10.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Rigel Pharmaceuticals (RIGL)
| 154.6 | 15.9 | -3.3 | -43.4 | -24.3 | 63.6 | -7.0 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Rigel Pharmaceuticals (RIGL)
|
46.0 | 868.2 | 276.8 | 321.9 | 33.0 | 78.8 | 2.8 | 2.1 |
| 81.0 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 263.3 | 16,261.1 | 1,054.4 | 755.9 | 5.7 | -- | 19 | 9.8 | |
| 70.0 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 54.3 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 106.1 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 354.8 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 530.1 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 589.3 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 | |
| 342.5 | 9,625.4 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 |
Shareholding Pattern
View DetailsAbout Rigel Pharmaceuticals (RIGL)
Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase... inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral interleukin receptor-associated kinases 1 and 4 (IRAK1/4) inhibitor, which is being advanced to Phase 1b study for the treatment of hematology-oncology, autoimmune, and inflammatory diseases, as well as to treat lower-risk myelodysplastic syndrome. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center (MDACC) for the development of olutasidenib in AML and other hematologic cancers with IDH1mutations; and the Collaborative Network for Neuro-Oncology Clinical Trial (CONNECT) to conduct a Phase 2 clinical trial to evaluate olutasidenib in combination with temozolomide in patients with high-grade glioma harboring an IDH1 mutation. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California. Read more
-
President, CEO & Director
Mr. Raul R. Rodriguez
-
President, CEO & Director
Mr. Raul R. Rodriguez
-
Headquarters
South San Francisco, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Rigel Pharmaceuticals (RIGL)
What is the current share price of Rigel Pharmaceuticals Inc (RIGL) Today?
The share price of Rigel Pharmaceuticals Inc (RIGL) is $45.99 (NASDAQ) as of 31-Aug-2026 14:34 EDT. Rigel Pharmaceuticals Inc (RIGL) has given a return of 55.63% in the last 3 years.
What is the current PB & PE ratio of Rigel Pharmaceuticals Inc (RIGL)?
The P/E ratio of Rigel Pharmaceuticals Inc (RIGL) is 2.77 times as on 28-Aug-2026.
The P/B ratio of Rigel Pharmaceuticals Inc (RIGL) is 2.06 times as on 28-Aug-2026, a 60 discount to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
2.20 |
2.06 |
2024 |
17.30 |
92.01 |
2023 |
-1.01 |
-0.88 |
2022 |
-0.44 |
-1.90 |
2021 |
-2.53 |
1.49 |
What is the 52 Week High and Low of Rigel Pharmaceuticals Inc (RIGL)?
The 52-week high and low of Rigel Pharmaceuticals Inc (RIGL) are Rs 52.24 and Rs 24.95 as of 01-Sep-2026.
What is the market cap of Rigel Pharmaceuticals Inc (RIGL)?
Rigel Pharmaceuticals Inc (RIGL) has a market capitalisation of $ 868 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Rigel Pharmaceuticals Inc (RIGL)?
Before investing in Rigel Pharmaceuticals Inc (RIGL), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.